DrugPatentWatch Database Preview

Litigation Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

« Back to Dashboard

Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Docket		Date Filed	2017-06-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	Defendant	Referred To
Parties	ACCORD HEALTHCARE INC.; ALKEM LABORATORIES LTD.; AMNEAL PHARMACEUTICALS LLC; AUROBINDO PHARMA U.S.A., INC.; AUROBINDO PHARMA USA LLC; BIOGEN INTERNATIONAL GMBH; BIOGEN MA INC.; CARIBE HOLDINGS (CAYMAN) CO. LTD.; CIPLA LIMITED; CIPLA USA INC.; DBA PURACAP CARIBE; GLENMARK PHARMACEUTICALS INC. USA; GLENMARK PHARMACEUTICALS LIMITED; GRAVITI PHARMACEUTICALS INC.; GRAVITI PHARMACEUTICALS PVT. LTD.; HETERO LABS LIMITED; HETERO LABS LIMITED UNIT-III; HETERO USA INC.; IMPAX LABORATORIES INC.; IMPAX LABORATORIES LLC; LUPIN ATLANTIS HOLDINGS SA; MACLEODS PHARMA USA, INC.; MACLEODS PHARMACEUTICALS LTD.; MSN LABORATORIES PRIVATE LTD.; MSN PHARMACEUTICALS INC.; PHARMATHEN S.A.; PRINSTON PHARMACEUTICAL INC.; PURACAP INTERNATIONAL LLC; S&B PHARMA, INC.; SANDOZ INC.; SAWAI PHARMACEUTICAL CO., LTD.; SAWAI USA INC.; SHILPA MEDICARE LIMITED; SLAYBACK PHARMA INDIA LLP; SLAYBACK PHARMA LLC; SUN PHARMA GLOBAL FZE; TEVA PHARMACEUTICALS USA INC.; TORRENT PHARMA INC.; TORRENT PHARMACEUTICALS LTD.; TWI PHARMACEUTICALS INC.; TWI PHARMACEUTICALS USA INC.; WINDLAS HEALTHCARE PVT. LTD.; ZYDUS PHARMACEUTICALS (USA) INC.
Patents	6,509,376; 6,926,907; 7,320,999; 8,399,514; 8,759,393
Attorneys	Aaron F. Barkoff; Adam Wyatt Poff; Alan Tenenbaum; Alejandro Menchaca; Alison M. Hill; Andrew Colin Mayo; Andrew E. Renison; Andy J. Miller; Anne Shea Gaza; Arthur G. Connolly , III; Benjamin J. Schladweiler; Bindu Ann George Palapura; Brian Sodikoff; Christopher B. Ferenc; Christopher M. Bruno; Christopher P. Galligan; David A. Bilson; David Ellis Moore; Dominick T. Gattuso; Don J. Mizerk; Dustin L. Taylor; Emily N. Winfield; Eric J. Fues; Erin M. Forbes; Erin R. Conway; Eve H. Ormerod; Frank D. Rodriguez; Frederick R. Ball; Gary Ji; George C. Lombardi; George J. Barry , III; Huiya Wu; Imron T. Aly; James B. Monroe; James E. Nealon; James P. Barabas; James S. Green , Jr.; Jeanette M. Roorda; Jeffer Ali; Jing Xia; John C. Phillips , Jr.; John E. Nappi; John R. McNair; Jonathan B. Turpin; Joseph E. Cwik; Joseph M. Reisman; Jovial Wong; Kelly E. Farnan; Kenton M. Walker; Kevin E. Warner; Laura P. Masurovsky; Li Feng; Loni L. Morrow; Mark Rubinshtein; Matthew M. Holub; Megan L. Meyers; Michael J. Gaertner; Michelle A. Herrera; Naomi L. Birbach; Neal C. Belgam; Patrick C. Gallagher; Paul W. Browning; Peter M. Kohlhepp; Philip D. Segrest; Philip Y. Braginsky; Pilar Gabrielle Kraman; Rachel P. Waldron; Rajendra A. Chiplunkar; Richard L. Renck; Samantha G. Wilson; Samuel Sherry; Sanya Sukduang; Sara E. Bussiere; Saukshmya Trichi; Scott B. Feder; Shailendra K. Maheshwari; Stamatios Stamoulis; Stephanie S. Riley; Stephen B. Brauerman; Steven J. Balick; Steven J. Moore; Thomas H. Ehrich; Thomas P. Krzeminski; Timothy F. Peterson; Timothy H. Kratz; Todd S. Werner; Vincent L. Capuano; William A. Rakoczy; William R. Zimmerman; Yun Wei
Firms	Bayard, P.A.; Connolly Gallagher LLP; Duane Morris, LLP; Greenberg Traurig, the Nemours Building; Heyman Enerio Gattuso & Hirzel LLP; Phillips, Goldman, McLaughlin & Hall, P.A.; Smith, Katzenstein, & Jenkins LLP; Stamoulis & Weinblatt LLC; Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-08-31	166	Stipulation of Dismissal	infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ʼ999 patent”) and 8,399,514…8,399,514 (“the ’514 patent”) (collectively, the “Asserted Patents”): Biogen MA Inc. v. Impax Laboratories, …Stipulation grants no rights to Impax under any patents or other proprietary rights. … 26 June 2017 1:17-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2019-03-07	236	Memorandum Opinion	infringement of U.S. Patent Nos. 6,509,376 ("the ' 376 patent"), 7,320,999 ("the ' …393 patent"), and 8,399,514 ("the ' 514 patent") (collectively, "patents-in-suit…; 999 patent"), 7,619,001 ("the ' 001 patent"), 7,803 ,840 ("the ' 840 patent…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent "specification	External link to document
2019-10-11	315	Stipulation of Dismissal	infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), and 8,399,514… alleging infringement of U.S. Patent No. 7,619,001 (“the ’001 patent”) by submission of Hetero’s ANDA…8,399,514 (“the ’514 patent”) by submission of Hetero’s Abbreviated New Drug Application (“ANDA”) No. 210500… Product”) prior to the expiration of the ’001 patent, i.e., June 20, 2020. 2. All claims… defenses, and counterclaims regarding the ’001 patent brought in C.A. No. 19-211 are dismissed without	External link to document
2019-10-24	317	Stipulation	4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the ’514 patent”) (collectively, the “Asserted …Asserted Claims” of the “Asserted Patent”) by submitting, or causing to be submitted, Abbreviated New Drug Application… WHEREAS claims 5, 7, 14, and 17-20 of the ’514 patent have not been asserted; WHEREAS, MSN’…(A)(vii)(IV) that, in its opinion, the Asserted Patent is invalid, unenforceable, or would not be infringed…Products prior to the expiration of the Asserted Patent in accordance with the labeling proposed in MSN	External link to document
2019-10-25	319	Stipulation	4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the ’514 patent”) (collectively, the “Asserted …Asserted Claims” of the “Asserted Patent”) by submitting, or causing to be submitted, Abbreviated New Drug Application… WHEREAS claims 5, 7, 14, and 17-20 of the ’514 patent have not been asserted; WHEREAS, Biogen…by Sandoz of the Asserted Claims of the Asserted Patent based Sandoz’s filing of ANDA No. 210414; …Prinston of the Asserted Claims of the Asserted Patent based on Prinston’s filing of ANDA No. 210512;	External link to document
2019-11-01	321	Stipulation	infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 (“…(“the ’001 patent”) 7,803,840 (“the ’840 patent), 8,759,393 (“the ’393 patent”), and 8,399,514 (“the …the ’514 patent”) by submission of Sawai’s Abbreviated New Drug Application (“ANDA”) No. 210285: Biogen… of claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent {01502985;v1 } Case 1:17-cv-00823-MN Document…that claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent are invalid for failure to comply with one or	External link to document